Equillium (EQ) Non-Current Deffered Revenue (2022 - 2023)

Equillium's (EQ) quarterly Non-Current Deffered Revenue came in at $2.4 million in Q3 2023, down 59.37% on a QoQ basis from $6.0 million in Q2 2023.

Equillium (EQ) Non-Current Deffered Revenue (2022 - 2023) Analysis & Trends

Equillium (EQ) has 2 years of Non-Current Deffered Revenue data on file, last reported at $2.4 million in Q3 2023.

On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $2.4 million in Q3 2023; TTM through Sep 2023 was $2.4 million, a N/A change from a year earlier, with the FY2022 full-year figure at $10.4 million, changed N/A from the prior year.
Non-Current Deffered Revenue for Q3 2023 stood at $2.4 million, down from $6.0 million in the prior quarter.
Over the last five years, Non-Current Deffered Revenue for EQ reached as high as $10.4 million in Q4 2022 and fell as low as $2.4 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	225.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Equillium	258.99 Mn	258.99 Mn	-	-

Download Data